Funded Health Care Startups in Menlo Park
Among the 11 most recent Health Care rounds listed for Menlo Park, one disclosed amount stands out: Orcabio’s $192M round on 2020-06-17.
Among the 11 most recent Health Care rounds listed for Menlo Park, one disclosed amount stands out: Orcabio’s $192M round on 2020-06-17. That figure dwarfs the next-largest disclosed rounds, including Tricida’s $125M (2022-10-19) and Ulab Systems’ $89M (2022-09-13), while most other disclosed entries fall between $1M and $70M (e.g., Enspectra Health $1M on 2022-03-16; Hello Heart $70M on 2022-05-02).
The date range in view runs from 2020-06-17 (Orcabio) through 2024-11-13 (The WiTT Group), with a noticeable cluster in 2022: at least five rounds land in 2022 (e.g., Ulab Systems 2022-09-13 $89M; Tricida 2022-10-19 $125M; Hello Heart 2022-05-02 $70M). Stage disclosures also skew unevenly: 4 of 11 rows show a disclosed stage label (Seed/Series A/Series D/Post-IPO Debt/Grant and others), while 2 of 11 are “Grant” and 2 of 11 are “Series Unknown,” plus one “undisclosed” amount. All rows are Menlo Park, California, United States with no alternative city names appearing.
Most recent rounds
11 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Menlo Park Health Care set, and how much larger is it than the rest?
Orcabio’s disclosed $192M round on 2020-06-17 is the largest; it is substantially above the next-largest disclosed amounts, including Tricida’s $125M (2022-10-19) and Ulab Systems’ $89M (2022-09-13). Most remaining disclosed rounds sit below $70M (e.g., Hello Heart at $70M on 2022-05-02; Enspectra Health at $1M on 2022-03-16).
Do the rounds cluster in a particular period based on the round dates shown?
Yes. At least five entries close in 2022—Hello Heart ($70M, 2022-05-02), Endovascular Engineering ($15M, 2022-04-05), Enspectra Health ($1M, 2022-03-16), Ulab Systems ($89M, 2022-09-13), and Tricida ($125M, 2022-10-19)—making 2022 the densest year in the 2020-06-17 to 2024-11-13 span.
Which stage/label categories appear most often, and how do they affect interpretation of deal size?
“Grant” appears twice (Enspectra Health $1M on 2022-03-16; Eclipse Regenesis $2M on 2021-08-26), while “Series Unknown” appears twice (Earlens is labeled Series Unknown with $19M on 2024-04-17, and Ulab Systems is labeled “Venture - Series Unknown” with $89M on 2022-09-13). There is also one “undisclosed” amount (The WiTT Group on 2024-11-13), which limits size-based comparisons for the newest entry.
How many of the listed rounds are within the most recent 12 months of dates shown, and what sizes do they include?
Within the 12-month window ending at the latest date shown (from 2023-11-13 through 2024-11-13), there are two entries: Langaware ($2M on 2023-10-04 is outside that window), and The WiTT Group ($undisclosed on 2024-11-13) plus Earlens ($19M on 2024-04-17). The disclosed amounts in that recent slice are therefore limited to $19M, alongside one undisclosed round.
Are there outliers besides the largest round that stand apart by scale?
Yes. Enspectra Health’s disclosed $1M grant (2022-03-16) is the smallest disclosed amount in the rows shown, which is materially below the rest of the disclosed spectrum (for example, $2M at Eclipse Regenesis on 2021-08-26; $6M at Alara Imaging on 2023-05-01; $15M at Endovascular Engineering on 2022-04-05). Together with Orcabio’s $192M, the dataset shows a wide dispersion rather than a tight band of deal sizes.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.